These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 1532631)

  • 1. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
    Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
    J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.
    Schulz JB; Klockgether T; Petersen D; Jauch M; Müller-Schauenburg W; Spieker S; Voigt K; Dichgans J
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1047-56. PubMed ID: 8089667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological and functional imaging in neurological and non-neurological Wilson's patients.
    Hermann W
    Ann N Y Acad Sci; 2014 May; 1315():24-9. PubMed ID: 24495036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.